Literature DB >> 21378756

Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.

Rabab A A Mohammed1, Ian O Ellis, Ali M Mahmmod, E Claire Hawkes, Andrew R Green, Emad A Rakha, Stewart G Martin.   

Abstract

Basal and triple-negative breast cancer phenotypes are characterised by unfavourable biological behaviour and outcome. Although certain studies have examined their pathological and molecular profile, the vascular characteristics of lymphatic and blood vessels have not been examined. Immunohistochemical staining with podoplanin, CD34 and CD31 was used to examine lymphatic and microvessel density, as well as vascular invasion in 197 basal-like and in 99 triple-negative breast tumours and compared against 200 non-basal and 334 non-triple-negative cases. All specimens were lymph node negative. Vascular invasion was identified as blood or lymphatic vascular invasion by the differential expression of markers. All measurements were correlated with clinicopathological features and prognosis. No significant difference was detected between the basal and triple-negative groups in terms of lymphatic or microvessel density or vascular invasion. However, both the basal and the triple-negative groups showed significantly higher microvessel density than did the non-basal and non-triple-negative groups (P=0.017 and P<0.001, respectively). Unlike microvessel density, no significant difference was detected in lymphatic density between the basal or triple-negative groups compared with their respective controls. Interestingly, vascular invasion, almost entirely lymphatic invasion, was detected in 27% of the basal and in 26% of the triple-negative groups with no significant difference in comparison with control groups. In both basal and triple negatives, vascular invasion was associated with poorer survival by univariate and multivariate analyses. The 20-year overall survival rate in basal-like tumours was 55% in vascular invasion-positive cases compared with 73% in vascular invasion-negative tumours (P=0.012), and 46% in triple-negative vascular invasion-positive compared with 79% in vascular invasion-negative tumours (P=0.001). Basal-like vs non-basal-like and triple-negative vs non-triple-negative tumours have similar vascular characteristics in terms of lymphatic vessel density and vascular invasion but higher microvessel density, suggesting that such groups may preferentially benefit from anti-angiogenic therapy. Vascular invasion was, in all phenotypes, almost entirely lymphatic vessel invasion and could stratify basal-like and triple-negative phenotypes into distinct prognostic groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378756     DOI: 10.1038/modpathol.2011.4

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  49 in total

1.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Authors:  Stylianos Drisis; Thierry Metens; Michael Ignatiadis; Konstantinos Stathopoulos; Shih-Li Chao; Marc Lemort
Journal:  Eur Radiol       Date:  2015-08-27       Impact factor: 5.315

2.  A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.

Authors:  Yujie Huang; Jiansong Fang; Weiqiang Lu; Zihao Wang; Qi Wang; Yuan Hou; Xingwu Jiang; Ofer Reizes; Justin Lathia; Ruth Nussinov; Charis Eng; Feixiong Cheng
Journal:  Cell Chem Biol       Date:  2019-06-06       Impact factor: 8.116

Review 3.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

Review 4.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

5.  Significance of histomorphology of early triple-negative breast cancer.

Authors:  Gábor Rubovszky; Zsolt Horváth; Erika Tóth; István Láng; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2012-03-14       Impact factor: 3.201

6.  Updating advances on recombinant human endostatin combined with radiotherapy for non-small cell lung cancer with brain metastasis.

Authors:  Xiao-Dong Jiang; Yun Qiao
Journal:  Transl Lung Cancer Res       Date:  2012-03

7.  Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer.

Authors:  Joanna A Niemiec; Agnieszka Adamczyk; Aleksandra Ambicka; Anna Mucha-Małecka; Wojciech M Wysocki; Beata Biesaga; Marek Ziobro; Ida Cedrych; Aleksandra Grela-Wojewoda; Małgorzata Domagała-Haduch; Joanna Wysocka; Janusz Ryś; Beata Sas-Korczyńska
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

8.  Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma.

Authors:  Bartosz Pula; Mateusz Olbromski; Andrzej Wojnar; Agnieszka Gomulkiewicz; Wojciech Witkiewicz; Maciej Ugorski; Piotr Dziegiel; Marzena Podhorska-Okolow
Journal:  Cell Oncol (Dordr)       Date:  2013-09-25       Impact factor: 6.730

9.  Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.

Authors:  C Henry; A Quadir; N J Hawkins; E Jary; E Llamosas; D Kumar; B Daniels; R L Ward; C E Ford
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-11       Impact factor: 4.553

10.  Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.

Authors:  Ying L Liu; Anurag Saraf; Shing M Lee; Xiaobo Zhong; Hanina Hibshoosh; Kevin Kalinsky; Eileen P Connolly
Journal:  Breast Cancer Res Treat       Date:  2016-05-25       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.